Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuomas Mirtti

Showing results (31-40 of 125) with videos related to

Pageof 13
Sort By:
Scientific Reports|August 4, 2022
The tumor and plasma cytokine profiles of renal cell carcinoma patientsMoon Hee Lee, Essi Laajala, Anna Kreutzman, et al.
Cancers|February 15, 2022
Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and ProgressionMaija Puhka, Lisse Thierens, Daniel Nicorici, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|July 12, 2019
Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomySusanna Lintula, Tuomas Mirtti, Antti Rannikko, et al.
Heliyon|July 22, 2024
Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomasArpit Aggarwal, Germán Corredor, Pingfu Fu, et al.
Plos One|July 22, 2015
Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder CancerMinna M Boström, Heikki Irjala, Tuomas Mirtti, et al.
International Journal of Cancer|September 10, 2005
Regulation of prostate cell collagen receptors by malignant transformationTuomas Mirtti, Camilla Nylund, Janika Lehtonen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|February 28, 2009
Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortalityTuomas Mirtti, Veli Jukka O Laine, Heikki Hiekkanen, et al.
The Prostate|July 10, 2025
Altered Glycosylation of PSA in Prostate Cancer TissueHannu Koistinen, Ruusu-Maaria Merivirta, Timo-Pekka Lehto, et al.
The International Journal of Biochemistry & Cell Biology|September 22, 2010
N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cellsAyush Dagvadorj, Shyh-Han Tan, Zhiyong Liao, et al.
Plos One|July 5, 2012
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerPaula Vainio, John-Patrick Mpindi, Pekka Kohonen, et al.
Pageof 13

Showing results (31-40 of 125) with videos related to

Sort By:
Pageof 13
Scientific Reports|August 4, 2022
The tumor and plasma cytokine profiles of renal cell carcinoma patientsMoon Hee Lee, Essi Laajala, Anna Kreutzman, et al.
Cancers|February 15, 2022
Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and ProgressionMaija Puhka, Lisse Thierens, Daniel Nicorici, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|July 12, 2019
Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomySusanna Lintula, Tuomas Mirtti, Antti Rannikko, et al.
Heliyon|July 22, 2024
Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomasArpit Aggarwal, Germán Corredor, Pingfu Fu, et al.
Plos One|July 22, 2015
Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder CancerMinna M Boström, Heikki Irjala, Tuomas Mirtti, et al.
International Journal of Cancer|September 10, 2005
Regulation of prostate cell collagen receptors by malignant transformationTuomas Mirtti, Camilla Nylund, Janika Lehtonen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|February 28, 2009
Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortalityTuomas Mirtti, Veli Jukka O Laine, Heikki Hiekkanen, et al.
The Prostate|July 10, 2025
Altered Glycosylation of PSA in Prostate Cancer TissueHannu Koistinen, Ruusu-Maaria Merivirta, Timo-Pekka Lehto, et al.
The International Journal of Biochemistry & Cell Biology|September 22, 2010
N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cellsAyush Dagvadorj, Shyh-Han Tan, Zhiyong Liao, et al.
Plos One|July 5, 2012
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerPaula Vainio, John-Patrick Mpindi, Pekka Kohonen, et al.
Pageof 13